Business Wire

GN-CORPORATION

14.3.2022 07:09:12 CET | Business Wire | Press release

Share
Nichi GLOW: Japanese Beta-Glucan, in Children With Autism Spectrum Disorder, Improves Behavior, Sleep, and Gut Microbiome in a Clinical Study

In the first such report, children with Autism spectrum disorder (ASD) showed improvement in behaviour, learning skills and sleep, after oral consumption of AFO-202 strain of black yeast Aureobasidium Pullulans produced Beta 1,3 -1,6 glucan (Nichi GLOW), published in BMJ Neurology Open (http://dx.doi.org/10.1136/bmjno-2021-000203 ). Beneficial reconstitution of gut microbiota was also reported with Nichi GLOW, which is unique from other beta glucans by its source, production method, and purity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220313005031/en/

Autism is a neurodevelopmental disorder affecting 1 in 44 children in the developed world, with multiple causes and varying severity of manifestation. These children are more likely to develop neurodegenerative diseases in later life. In the study, Nichi GLOW intake improved CARS score and communication skills (https://www.youtube.com/watch?v=reJOjBMKSg4 ). Nichi GLOW controlled enterobacteria, a gut microbiome producing harmful proteins like curli and amyloid, leading to Alpha-synuclein misfolding and aggregation in the neurons, a cause of the disease (https://doi.org/10.1101/2021.10.26.21265505 ). Synucleinopathy spreading through gut-brain-axis to the brain, might cause Parkinson’s or Dementia, therefore, it’s worth studying the prophylaxis of Nichi Glucan range of products in neurodegenerative conditions, as microglia activation is one of the mechanisms of their action in brain (https://doi.org/10.1016/j.jns.2021.117554 ), says Dr. Raghavan, the principal investigator.

The findings were presented in a webinar commemorating Autism Sunday (https://www.ncrmniche.org/autismsunday2022/proceedings/index.html ), organized by Jesuit Antonyraj memorial Inter-disciplinary Center for Advanced Recovery and Education (JAICARE). Research conducted in Japan unraveled the hidden potentials (https://doi.org/10.1101/2021.08.05.21261640 ), of this ß-glucan; thanks to a wholesome ecosystem in Japan aiding development of novel solutions, which together with the trans-world inter-disciplinary network of healthcare expertise of GN Corp have made this path-breaking feat possible, commented the scientists. https://sponsored.bloomberg.com/article/jco/japan-where-high-tech-meets-high-value-foreign-direct-investment

Nichi Glucan range of products were approved as food additives in Japan in 1996 and don’t contain any commonly notified allergens. They are unique, being produced as an exo-polysaccharide by novel strains of Aureobasidium Pullulans in a GMP certified facility in Japan and exported in different brands: Nichi-GLOW, Neu-REFIX, Nichi Glucan & Nichi Glucan-REFIX ; not intended to diagnose, treat, cure, or prevent any disease & approval status may vary between countries. Publications are meant for academic and research initiative purposes; not to be construed as medical advice. Physicians’ advice is recommended for specific health queries.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

One Biosciences Receives BOOST Funding From Paris-Saclay Cancer Cluster to Advance the First Single-Cell Assay Approach for ADC Therapies22.6.2026 22:15:00 CEST | Press release

One Biosciences, a techbio company pioneering clinical-grade single-cell tumor profiling, today announced financial support via a Paris-Saclay Cancer Cluster (PSCC) BOOST grant to develop the first single-cell assay for antibody-drug conjugates (ADC) therapies in oncology. The rapid growth of ADCs is driving demand for more sophisticated biomarker strategies. By capturing tumor complexity at cellular resolution, single-cell profiling has the potential to enhance patient selection and support the development of next-generation ADCs. Ultimately, it will help match the right patients to the right therapies, maximizing therapeutic benefit. The PSCC BOOST-funded project seeks to bring a new level of precision to ADC development. It will be conducted in collaboration with Adcytherix, a clinical-stage biotech company developing differentiated ADCs for cancers with high unmet medical need. The collaboration will combine Adcytherix’s expertise in ADC development with One Biosciences’ AI-powered

Interactive Brokers Expands AI Integration Capabilities – Adding ChatGPT and Grok to Its Growing Suite of Agentic Trading Tools22.6.2026 16:00:00 CEST | Press release

Additional Asset Classes Available Including Options and Futures Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the expansion of its agentic trading capabilities with the addition of ChatGPT and Grok, further broadening a growing ecosystem of AI platform integrations that began with Claude. Available through certified AI connector marketplaces across multiple leading platforms, these integrations allow clients to research, analyze, and generate instructions with speed and efficiency to uncover new trading and investing opportunities instantly. With this release, Interactive Brokers also extends the selection of products available for order instructions to include support for options, futures and futures options in addition to equities and ETFs. “We continue to see growing interest from investors in using artificial intelligence as a more natural way to interact with financial markets,” said Milan Galik, Chief Executive Officer of Interactive Brokers. “A

IQM Named Among Quantum Collaborators in HPE's New Hybrid Quantum-HPC Platform22.6.2026 15:22:00 CEST | Press release

The collaboration will advance practical and scalable hybrid classical-quantum applications. This follows IQM's first on-premises quantum computer installation in the United States, at Oak Ridge National Laboratory. IQM has sold 23 quantum systems globally to date and intends to list on Nasdaq in the United States by mid 2026. Hewlett Packard Enterprise has named IQM Quantum Computers among the companies collaborating on its hybrid classical-quantum computing platform, announced at HPE Discover Las Vegas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622035759/en/ IQM Radiance quantum computer at HPE Discover Las Vegas 2026 IQM, a global leader in full-stack superconducting quantum computers, is contributing superconducting quantum processor technology to the effort, in which HPE is integrating multiple quantum modalities with its Cray supercomputing infrastructure. This collaboration strengthens IQM's global expansion p

Return Abuse Goes Mainstream as Nearly Half of Consumers Use AI in Return Claims, New Riskified Research Finds22.6.2026 14:30:00 CEST | Press release

New global study shows normalization of strategic returns, widening regional differences, and rapid AI adoption reshaping ecommerce post-purchase risk Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, today released a new global report, “Rewriting the Rules on Returns”, exploring how consumer attitudes and behaviors around ecommerce returns are evolving in the age of artificial intelligence (AI). The Riskified-commissioned study, conducted by eTail Insights, is based on a survey of 2,091 consumers across seven countries, alongside in-depth interviews with senior leaders from many of the largest retail companies in the world. The research finds that return abuse behaviors are increasingly normalized, while nearly half of consumers already use generative AI tools to assist with return or refund claims. At the same time, merchants are responding by tightening return policies, shortening return windows, and deploying advanced AI detection to better

Forrester Unveils Agendas For 2026 Technology & Innovation Forums In North America And EMEA22.6.2026 14:00:00 CEST | Press release

The Forums will equip technology leaders with the capabilities needed to operationalize AI and build high-performing IT organizations that deliver measurable business outcomes Forrester (Nasdaq: FORR) today announced the full conference agendas for its Technology & Innovation Forum Central (Austin, September 14–15, 2026), Technology & Innovation Forum EMEA (London, September 30–October 1, 2026), and Technology & Innovation Forum East (New York City, November 4–5, 2026). This year’s theme, “The IT Singularity,” dives into the new AI era in which AI has become ubiquitous and no longer a competitive advantage on its own. To succeed, technology leaders including chief information officers, chief data officers, and chief AI officers need to integrate AI into their operating models, modernize software development and IT operations, strengthen data and governance practices, and align technology investments with business strategy. Across the Forums, tech leaders and their teams will learn how

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye